Tomas G. Neilan

Harvard University — United States

Medicine · Health Sciences

66h-index20.3kcitations404works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiac Imaging and Diagnostics(89), Chemotherapy-induced cardiotoxicity and mitigation(83), Cancer Immunotherapy and Biomarkers(68), Cardiovascular Function and Risk Factors(52), HIV-related health complications and treatments(28)

Publications403 total

Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer
Journal of the American Heart Association·2025· 1 citedOpen Access
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects
JAMA Oncology·2025· 1 cited
Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy
JAMA Cardiology·2025Open Access
Abstract 4357286: Atorvastatin and Pulse Wave Velocity in Anthracycline-based Chemotherapy
Circulation·2025
Effect of continuous positive airway pressure on ventricular remodeling of patients with combined diabetes mellitus and obstructive sleep apnea: a cross-sectional study and follow-on randomized clinical trial
International Journal of Cardiology·2025· 2 citedOpen Access
Predictors of Long‐Term Survival in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
Journal of the American Heart Association·2025· 2 citedOpen Access
Adult thymectomy is associated with increased mortality risk from cancer but not cardiovascular disease
Blood Advances·2025· 2 citedOpen Access
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure
Leukemia & lymphoma/Leukemia and lymphoma·2025Open Access
ATORVASTATIN AND LEFT ATRIAL FUNCTION DURING ANTHRACYCLINE-BASED CHEMOTHERAPY
Journal of the American College of Cardiology·2025Open Access
Associations Between Social Determinants of Health, Allostatic Load, and Anthracycline Cardiotoxicity in a Diverse Patient Population
Journal of the American Heart Association·2025· 1 citedOpen Access
Racial and Ethnic Disparities in Cardiotoxicity in Patients With Cancer Treated With Anthracyclines
Journal of the American Heart Association·2025· 1 citedOpen Access
Immune checkpoint inhibitors and myocardial infarction
Journal of Thrombosis and Thrombolysis·2025· 5 cited
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Journal for ImmunoTherapy of Cancer·2025· 5 citedOpen Access
Polygenic susceptibility to dilated cardiomyopathy underlies peripartum, alcohol-induced, and cancer therapy-related cardiomyopathies
2025· 3 citedOpen Access
Atorvastatin and Myocardial Extracellular Volume Expansion During Anthracycline-Based Chemotherapy
JACC CardioOncology·2025· 9 citedOpen Access
Atorvastatin and left ventricular global circumferential strain during anthracycline-based chemotherapy
Journal of Cardiovascular Magnetic Resonance·2025· 2 citedOpen Access
Glucagon-like Peptide‐1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors
European Journal of Cancer·2024· 14 cited
Cardiovascular Safety in Oncology Clinical Trials
JACC CardioOncology·2024· 9 citedOpen Access
Elucidating the Signal from the Noise
JACC CardioOncology·2024Open Access
Abstract 4138101: CAR-T-associated Cardiovascular Events are Associated with Increased Resource Utilization
Circulation·2024· 1 cited
page 1 of 21Next →

Frequent Co-authors

Michael Jerosch‐Herold(14), Paaladinesh Thavendiranathan(12), Anju Nohria(12), Sarju Ganatra(12), Raymond Y. Kwong(12), Ana Barac(11), Michael G. Fradley(11), Ravi V. Shah(11), Kerry L. Reynolds(10), Otávio R. Coelho‐Filho(10), Javid J. Moslehi(9), Syed Mahmood(9), Ryan J. Sullivan(9), Alexander R. Lyon(8), Stéphane Éderhy(8), Franck Thuny(7), Magid Awadalla(7), John D. Groarke(7), Michael H. Picard(7), Daniel A. Zlotoff(7)